MyDx Inc. (fka MYDX)

[MightyX]

Called my broker this morning, unfortunately my buy order yesterday at .01 that got filled at .0082 was against company policy but I’m able to keep the shares but cannot put in a buy order at .01 until the share price reaches .01 and I doubt highly that I’m the only shareholder/investor that is eager to improve/start a position with MYDX. I believe once shareprice trades above a penny for more than a minute, more new investors will be entering the equation and volume will increase and share price will quickly make it to .02 and beyond with the assistance of traders doing what they do best. Traders are accumulating I believe and are benefiting from the downward share price movement and are waiting for new buyer volume that will result from either an industry positive announcement or a MYDX PR releasing positive status report. MYDX is doing good things for people and people are doing good things for MYDX.

MYDX.Asia, Ltd.in Hong Kong.changed.its name.to.Red Rock.Canyon,.Ltd?.Cool!!! It’s still in Hong Kong and is still the same privately held company that MYDX Asia, Ltd. was? Cool!!! Privately held company, meaning it does not answer to SEC. What’s interesting is how Red Rock Canyon in general can be found in Nevada. Kinda neat, it’s like MYDX bringing a piece of Nevada with them to Hong Kong under the name that they changed from MYDX Asia, Ltd. to Red Rock Canyon, Ltd. Cool!!! Any comments made about Red Rock Canyon, Ltd. are merely opinions.

https://www.asiafitnesstoday.com/2017/07/18/mydx-files-complaint-against-former-chief-operating-officer-protects-unique-aerodx-diagnostic-platform-and-addresses-toxic-financiers-unauthorized-conversion/

Gee, I wonder why Asia would care about MYDX lawsuit to protect AeroDX. I’m guessing because they are planning to launch the AeroDX analyzer after winning multimillion dollar suit against the alleged in the MYDX filed complaint to the court.

The only argument isn’t that MYDX doesn’t still have a presence in China because it does, it’s that the name may have changed but it’s the same company and it’s “live” and for one big reason as far as I’m concerned and that is to utilize the
http://www.chinasciencetech.com website for online sales to the China market specifically the Aero, Aqua, and OrganaDX’s when they become available.

Evidence MYDX is still a tenant. All other claims that the office is vacant is mistaken and misleading to the public:
http://www.loopnet.com/Property-Record/6335-Ferris-Square-San-Diego-CA-92121/Mzp6TMq4A/Tenant/

MYDX trading and closing above 200 dma is considered bullish!! And it has continued this trend for 11 consecutive trading days and 17 above the 50 dma. Once volume returns to 30 million, traders will run up the share price again.

All it will take for the next 20x run is one multimillion dollar short term renewable contract. When will we know the starting point of the next 20x run? Well, I’d say the opening bid on the next 100 million share trading day will indicate the starting point of next 20x run which if MYDX gets to .01 before next PR and investors who can only trade at .01+ finally get a chance to improve their position rally the share price to .02 and then we get a PR revealing revenue generating renewable contract in the multi millions, MYDX will soar to .40 in a matter of weeks thereafter and no reverse split. Then, MYDX medical device designation for one or both products with a follow up multimillion dollar renewable contract begins next 20x run starting between .15-.20 rallying share price to $3-$4 and makes anyone who bought and held 1 million shares during the next week or so multimillionaires for an initial investment of $25k or less in about 2 years or less and then MYDX uplists to NASDAQ and starts trading above $10 a share.

Happy 2018 and beyond long holders. It has been worth the wait and countless hours on a daily basis trying to figure out why it’s not possible to consider MYDX as the biggest play in mj. It’s time people know MYDX. In a few weeks, more and more will get to know and everyone will win with MYDX except for those who lose money when share price goes up.

Now, MYDX forms exclusive partnership with Highsmen Genetics to create tailor-made strains designed specifically to remedy individual physiologies. This is one significant addition to the Phylos Bioscience partnership in creating a MYDX data powerhouse, the strongest user-data generating force and soon to be official, a significant revenue generator for MYDX improving shareholder confidence.
MYDX exclusive partnership with Highsmen, MYDX partnership with Phylos Bioscience. See the similarity and the direction MYDX is going? Data utilization not only from the CannaDX but data collected from these other two sources to manufacture/grow products/plants specifically engineered/created specifically for the consumer/patient. The science is beyond most investors but once it proves practicality by monetizing, investors won’t have to know the science, they just want to get paid. Paid they will get once monetization occurs from the result of this powerful partnership chain. It’s unique approach will prove more effective, sustainable and influential and therefore more profitable than the competition including GW.

This is.the.beginning of.something.huge. I.was.hoping in my lifetime something like this would happen with MYDX and it could happen in 5 years or less!

Ok, months back(references to follow) I suggested how human Genomics are important because it is what MYDX has been saying all along, that each individual physiology is unique and so is how each physiology reacts to same cannabis strain. Phylos fits in perfect with the concept of cross referencing CannaDX sample test data with Phylos cannabis Genomics and now a feeling can be associated with a degree of accuracy to a specific cannabis genome, so now, the individual, not even knowing his/own gene sequence can identify with a specific cannabis plant for a specific ailment relief.

This cross-referencing of data makes each entity(Phylos and MYDX) codependent for generating even more meaningful data to offer the market place. This is the next step in the ultimate cost-effective human/cannabis genome project for medicinal purposes.

I’m not sure what he next step after this would be but eventually, hopefully in my lifetime as well MYDX will be involved in cross-referencing individual Genomics with cannabis Genomics where the individual would know with absolute certainty based on historical data what cannabis product to purchase to remedy a specific ailment or to provide a wanted reaction.

“Phylos uses genome sequencing technology to generate DNA “barcodes” that uniquely identify cannabis varieties. This information is important for basic scientific research, and it also serves as proof of existence that can be used to defend against attempts at patenting.”
http://www.phylosbioscience.com/about/data-policy/ ;
Perhaps this can be used to fight of GW attempts at CBD patenting.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133208585 ;
“Last year, the China Food and Drug Administration approved the sequencer as a medical device, allowing its use in clinical genetic testing...”

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132234994 ;
http://www.prnewswire.com/news-releases/pharma-and-biotech-companies-significantly-investing-in-rd-focus-on-rising-demand-for-advanced-medicines-628164013.html Wow, according to this, est. 50Billion dollars is used by these companies alone are using on R&D investments specifically in "advanced medicine" alone:

"In just over a year ago, it's been estimated $50 billion was invested on pharmaceutical Research and Development activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected to propel the biotechnology services outsourcing market growth. Biotechnology and Pharmaceutical Companies with developments and recent market activity this week include: Moleculin Biotech, Inc., (NASDAQ: MBRX), XBiotech Inc. (NASDAQ: XBIT), GTx, Inc. (NASDAQ: GTXI), Agenus Inc. (NASDAQ: AGEN) and TrovaGene Inc. (NASDAQ: TROV)"

How many of these companies are applying research to the use of medicinal cannabis in the rising medicinal cannabis market? They are clearly focusing their attention on non-cannabis markets and will go through MYDX when the time is right for them which is most likely when medicinal cannabis is legal at the federal level. The more years, the more they will have to pay for all of MYDX's R&D investments in advanced medicinal cannabis vape pen. What effect will this have on current MYDX investors?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132627843 ;
MYDX is the solution to an EXPOSED PROBLEM: unsafe black market weed. Before it was just black market weed, this by itself is not effective for MYDX but now that it's UNREGULATED HARMFUL BLACK MARKET WEED, the only chance consumers have of not being harmed by illegal unregulated weed is the MYDX CannaDX chemical analyzer with proven successful results! Once MYDX becomes PREMIER HOUSEHOLD CANNABIS QUALITY CONTROL backed by consumers and consumer confidence, what other companies will be around to compete? What direct competition does MYDX have?

MYDX major reasons why MYDX data is so valuable (followed by reference link):

"However, as MyDx began to analyze the data it accumulated from its testing devices, a much darker picture appeared - you cannot trust what dispensaries sell you."

"Today, if you were to go into any dispensary and ask for "Blue Dream", what do you think you would get? Would you get "Blue Dream"?
According to MyDx data, the answer is unequivocally NO!
Unfortunately, not all Blue Dreams are created equal, unveiling the biggest lie in cannabis. Whereas consumer products outside of cannabis enjoy a higher level of consistency and reliability brought on by stricter enforcement of consumer laws, the same cannot be said about the cannabis industry."

"Fortunately for MyDx users, brand names take a back seat to chemical profiles as MyDx tracks data based on sensory responses, interpreted chemical profiles, and an associated feeling or relief. So while you can't trust the brand name you purchase, you can Trust and Verify® chemical profiles and track how those profiles make you feel using MyDx, which has created another opportunity: green Active Pharmaceuticals Ingredients (gAPI)
"I believe extraction and formulation into a concentrate that can be delivered consistently to help patients find relief for their ailments and symptoms is the next logical step to achieving some level of consistency in the industry," stated Daniel Yazbeck, Chief Executive Officer of MyDx."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making ;

MYDX Why gAPI is so valuable (link reference to follow):

"...we are now identifying the specific green Active Pharmaceutical Ingredients (gAPI) that can be derived from cannabis, as well as the dosage of each ingredient that should go into a formulation so it can be tailored for a specific therapy. This information not only supports an active engaged community, but also provides the basis for our Company to partner, sell and supply smart devices and formulations to the various communities we service so they can benefit from tailored cannabis therapies that meet their specific needs."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making ;

MYDX is HIPPA compliant, important? You be the judge after considering the following (reference links to follow):

"We are finally getting to the heart of what ailments people are tracking and more importantly, what unique chemicals profiles are helping them find relief," stated Yazbeck. "By mining this HIPPA Compliant Data, we are now identifying the specific green Active Pharmaceutical Ingredients (gAPI) that can be derived from cannabis, as well as the dosage of each ingredient that should go into a formulation so it can be tailored for a specific therapy."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making ;

Is HIPPA compliance important (reference link to follow)?

"When dealing with patient ePHI, having a HIPAA compliant provider offers practitioners multiple benefits and peace of mind against impending audits."

http://blog.corespace.com/the-benefits-of-a-hipaa-compliant-provider ;

Is this product helping consumers determine whether or not they want to smoke a certain strain of cannabis before they smoke it? Is this product helping consumers communicate with MYDX verification that a certain strain could have a certain effect for someone interested in similar results as research before they invest in a cannabis purchase? The answer to these quintessential questions is undoubtedly YES and this is what I love about MYDX and what it is doing for consumers through CannaDX. Big deal if someone tells me a certain strain works for them, I want to be able to test it for myself. MYDX will allow me to test a strain I've had that made me feel sick and caused vomiting and dizziness. I love that I will be able to test what strain that was so I know through the "trust and verify" process that I will never put that strain in my body ever again! This is just cannabis, MYDX is so much more but what it accomplishes is exactly what it set out to do from day one and that is allow consumers the opportunity to "trust and verify" something before they expose it to their bodies, and as far as AeroDX, I believe, there will be sensors you can place in a room that will monitor the air so that before someone enters it, they will be able to know if the air is toxic. For sure, if a room's air is toxic after you enter it, AeroDX will let you know. If someone hates this product or company, it can't be for these reasons, so that's what I will never understand about people who say they hate this company and products. I'm not going to ask questions leading to the conclusion that people involved in companies such as big pharma just don't want MYDX to succeed because it is a threat to their market share in their industry.